Enrichment strategies will be sought, but initially there are no validated biomarkers or clinical syndromes that would permit determining which patient population is most likely to respond to c‐Abl inhibitors—indeed, we believe that these therapies should be beneficial for all PD patients. The gene discussed is ABL1; the disease is Parkinson disease.